Unity Biotechnology, Inc. (UBX)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Anirvan Ghosh Ph.D. | CEO & Director | 940.4k | -- | 1964 |
| Dr. Nathaniel E. David A.B., Ph.D. | Co-Founder & Executive Director | 40k | -- | 1968 |
| Mr. Alexander Hieu Nguyen J.D. | Chief Legal Officer, Head of Operations & Corporate Secretary | 589.4k | -- | 1977 |
| Dr. Jan M. van Deursen | Founder | -- | -- | -- |
| Mr. Daohong Zhou M.D. | Founder | -- | -- | -- |
| Dr. Przemyslaw Sapieha Ph.D. | Chief Scientist | -- | -- | -- |
| Ms. Alicia Tozier M.B.A. | Chief Strategy Officer | -- | -- | -- |
Unity Biotechnology, Inc.
- Sector:?
- Healthcare
- Industry:? Biotechnology
- Full Time Employees:?
- 19
Description
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.
Corporate Governance
Upcoming Events
November 4, 2024 at 9:30 PM UTC
Unity Biotechnology, Inc. Earnings Date